Randomized Clinical Study of a Histamine H3 Receptor Antagonist for the Treatment of Adults with Attention-Deficit Hyperactivity Disorder
CNS Drugs,

Weisler RH et al. – Bavisant, a highly selective, wakefulness–promoting H3 antagonist, did not display significant clinical effectiveness in the treatment of adults with attention–deficit hyperactivity disorder.

Methods
  • his randomized, double-blind, placebo- and active-controlled, parallel-group, multicentre study evaluated three dosages of bavisant (1 mg/day, 3 mg/day or 10 mg/day) and two active controls in adults with ADHD.
  • The study consisted of a screening phase of up to 14 days, a 42-day double-blind treatment phase and a 7-day post-treatment follow-up phase.
  • Efficacy and safety assessments were performed.
  • The study was conducted at 37 study centres in the US from April 2009 through January 2010.
  • Men and women aged 18-55 years with an established diagnosis of ADHD as confirmed by clinician and self-report diagnostic measures were enrolled.
  • Participants were randomly assigned equally to one of six treatment groups: placebo, bavisant 1 mg/day, 3 mg/day or 10 mg/day, atomoxetine hydrochloride 80 mg/day or osmotic-release oral system (OROS) methylphenidate hydrochloride 54 mg/day.
  • The primary efficacy endpoint was the change in the Attention Deficit Hyperactivity Disorder Rating Scale, Version IV (ADHD-RS-IV) total score from baseline (day 1) to the end of the treatment phase (day 42), and included all randomized participants who received one or more doses of study drug and had baseline and one or more post-baseline assessments (intent-to-treat [ITT] population).
  • Safety assessments included treatment-emergent adverse events (TEAEs), laboratory tests and ECG readings.

Results
  • 430 participants were randomized, 424 received one or more doses of study medication and 335 (78%) of those randomized completed the study.
  • Study participants had a mean age of 33.9 years and were predominantly White men.
  • Mean treatment duration ranged from 31.4 to 38.8 days across groups.
  • Mean change from baseline in the total ADHD-RS-IV score at day 42 (primary efficacy endpoint) was -8.8 in the placebo group versus -9.3, -11.2 and -12.2 in the bavisant 1 mg/day, 3 mg/day and 10 mg/day groups, respectively; the change in the 10 mg/day group was not statistically superior to placebo (p = 0.161), and hence statistical comparisons of the 1 mg/day and 3 mg/day groups with placebo based on a step-down closed testing procedure were not performed.
  • Mean change from baseline in the total ADHD-RS-IV score at day 42 was superior to placebo in the atomoxetine (-15.3) and OROS methylphenidate (-15.7) groups (p < 0.005).
  • Secondary efficacy assessments demonstrated a similar pattern with a non-significant trend towards improvement in the bavisant groups.
  • The two lower dosages showed a good tolerability profile, but the higher dosage of bavisant was less well tolerated, as evidenced by the incidence of total TEAEs (61.8%, 82.4%, 89.0%), and discontinuations due to TEAEs (4.4%, 7.4%, 19.2%) in the bavisant 1 mg/day, 3 mg/day and 10 mg/day groups, respectively, compared with 58.9% and 2.7%, respectively on placebo.
  • In the atomoxetine and OROS methylphenidate groups, the incidence of total TEAEs was 83.8% and 82.4% and discontinuations due to TEAEs was 10.8% and 8.8%, respectively.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Family Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Family Medicine Articles

1 A comparison of the effects of hatha yoga and resistance exercise on mental health and well-being in sedentary adults: A pilot study Complementary Therapies in Medicine, June 11, 2014    Clinical Article

2 Short-term effects of a manual therapy protocol on pain, physical function, quality of sleep, depressive symptoms, and pressure sensitivity in women and men with fibromyalgia syndrome: A randomized controlled trial The Clinical Journal of Pain, June 9, 2014    Clinical Article

3 Depression treatment by withdrawal of short-term low-dose antipsychotic, a proof-of-concept randomized double-blind study Journal of Affective Disorders, June 16, 2014    Clinical Article

4 Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications BMJ, June 12, 2014    Clinical Article

5 A comparison of the effects of hatha yoga and resistance exercise on mental health and well-being in sedentary adults: A pilot study Complementary Therapies in Medicine, June 19, 2014    Clinical Article

6 The effect of green tea on blood pressure and lipid profile: A systematic review and meta-analysis of randomized clinical trials Nutrition, Metabolism & Cardiovascular Diseases, March 27, 2014    Evidence Based Medicine    Review Article

7 Risk of myocardial infarction and stroke in bipolar disorder: A systematic review and exploratory meta-analysis Acta Psychiatrica Scandinavica, May 30, 2014    Evidence Based Medicine    Review Article

8 Impact of mindfulness-based cognitive therapy on health care utilization: a population-based controlled comparison Journal of Psychosomatic Research, June 26, 2014    Clinical Article

9 Prognostic impact of the serum heart-type fatty acid-binding protein (H-FABP) levels in patients admitted to the non-surgical intensive care unit Clinical Research in Cardiology, May 23, 2014    Clinical Article

10 Effect of dietary restriction on peripheral monoamines and anxiety symptoms in obese subjects with metabolic syndrome Psychoneuroendocrinology, June 24, 2014    Clinical Article

11 Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder Neuropsychopharmacology, June 2, 2014    Clinical Article

12 Duloxetine-bupropion combination for treatment-resistant atypical depression: A double-blind, randomized, placebo-controlled trial European Neuropsychopharmacology, May 22, 2014    Clinical Article

13 The association of internet addiction symptoms with anxiety, depression and self-esteem among adolescents with attention-deficit/hyperactivity disorder Comprehensive Psychiatry, June 17, 2014    Clinical Article

14 The impact of anxious symptoms in the remission of depressive symptoms in a clinical trial for depression: Follow-up of six months Journal of Affective Disorders, June 10, 2014    Clinical Article

15 Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression – A systematic review Psychiatry Research, June 18, 2014    Evidence Based Medicine    Review Article

16 Efficacy and tolerability of antidepressants for sub-threshold depression and for mild major depressive disorder Journal of Affective Disorders, June 16, 2014    Evidence Based Medicine    Review Article

17 Changes in circulating leptin levels during acute stress and associations with craving in abstinent smokers: A preliminary investigation Psychoneuroendocrinology, June 20, 2014    Clinical Article

18 Individual mindfulness-based cognitive therapy (MBCT) and cognitive behavior therapy (CBT) for treating depressive symptoms in patients with diabetes: Results of a randomized controlled trial Diabetes Care, June 6, 2014    Clinical Article

19 Depression with atypical features and increase in obesity, body mass index, waist circumference, and fat mass : a prospective, population-based study JAMA Psychiatry, June 13, 2014    Clinical Article

20 Self-relevant disgust and self-harm urges in patients with borderline personality disorder and depression: A pilot study with a newly designed psychological challenge PLOS ONE, June 27, 2014    Clinical Article

Indexed Journals in Family Medicine: American Family Physician, Archives of Family Med, Annals of Family Medmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close